PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

The continued evolution of treatment protocols and imaging modalities for the management of retinal diseases offer ... for the management of geographic atrophy secondary to age-related macular ...

Ocugen is developing OCU410 as a 1-time gene therapy for the treatment of geographic atrophy. It utilizes an AAV delivery platform for the retinal delivery of the ROR Related Orphan Receptor A gene.

The continued evolution of treatment protocols and imaging modalities for the management of retinal diseases offer ... for the management of geographic atrophy secondary to age-related macular ...

Whether it’s something as common as cataracts or more complex conditions like progressive retinal atrophy (PRA), understanding these health risks is key. In this article, we’ll explore the breeds most ...

(Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE ® (pegcetacoplan) for the every-other-month treatment of adult patients with geographic atrophy ...

In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA lesion growth of 66% at 3 months.

was evaluated using a preclinical animal model reproducing the key clinical characteristics of geographic atrophy seen in patients. These include degeneration of the retinal pigment epithelium ...

Australia's Therapeutic Goods Administration has approved the use of a new and first treatment for geographic atrophy - a disease which causes severe, progressive central vision loss and is a leading ...